Listed by the USPTO as ALLEN, SARAH ELIZABETH
Tech Center 1600 • Art Units: 1637
This examiner grants 57% of resolved cases
ALLEN, SARAH ELIZABETH works in Tech Center 1600 and Art Unit 1637. The profile covers 30 resolved cases, with a 56.7% allowance rate and a 33.3% interview lift. Median time to allowance is 1314 days. The small record calls for caution in drawing broad conclusions, but the interview figure indicates a potentially useful prosecution avenue.
Top organizations are President and Fellows of Harvard College, The Trustees of the University of Pennsylvania, and Eligab Tx LLC. The leading firms are Knobbe, Martens, Olson & Bear, LLP, WOLF GREENFIELD & SACKS, P.C., and CANTOR COLBURN LLP - UCONN.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18120030 | OLIGONUCLEOTIDES FOR APP MODULATION | Final Rejection | UNIVERSITY OF MASSACHUSETTS |
| 17980883 | METHODS OF GENOME EDITING INCLUDING CONTROLLED OPENING OF CHROMATIN | Final Rejection | Wisconsin Alumni Research Foundation |
| 18485930 | RESCUE STRATEGIES FOR BEST1 LOSS- AND GAIN-OF-FUNCTION MUTATIONS | Non-Final OA | University of Rochester |
| 18269846 | CHEMICAL SUBSTANCE EVALUATION SYSTEM USING MULTICOLOR LIGHT-EMITTING CELLS | Non-Final OA | TOHOKU UNIVERSITY |
| 18459548 | ACYCLIC THREONINOL NUCLEIC ACID | Non-Final OA | AGC Inc. |
| 18323245 | METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES | Non-Final OA | President and Fellows of Harvard College |
| 18028183 | PRIME EDITING GUIDE RNAS, COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME | Final Rejection | President and Fellows of Harvard College |
| 18563790 | CORRECTION OF DUCHENNE MUSCULAR DYSTROPHY MUTATIONS WITH ALL-IN-ONE ADENO-ASSOCIATED VIRUS-DELIVERED SINGLE-CUT CRISPR | Non-Final OA | The Board of Regents of The University of Texas System |
| 17717697 | GENE EDITING TO CORRECT ANEUPLOIDIES AND FRAME SHIFT MUTATIONS | Final Rejection | The Trustees of Columbia University in the City of New York |
| 18630651 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF GLYCOGEN STORAGE DISORDERS | Non-Final OA | University of Connecticut |
| 17997312 | MODIFIED NUCLEIC ACIDS ENCODING ASPARTOACYLASE (ASPA) AND VECTOR FOR GENE THERAPY | Non-Final OA | Pfizer Inc. |
| 18709415 | GENE THERAPY FOR TREATMENT OF MUCOPOLYSACCHARIDOSIS IIIA | Non-Final OA | The Trustees of the University of Pennsylvania |
| 18253919 | PMO-BASED UTROPHIN::LET-7C MIRNA SITE BLOCKING OLIGONUCLEOTIDES (SBOS) FOR TREATING DUCHENNE MUSCULAR DYSTROPHY (DMD) | Final Rejection | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 18486146 | M6A-COUPLED EFFECTOR PROTEIN EXPRESSION SYSTEM AND METHODS OF MAKING AND USING SAME | Non-Final OA | Duke University |
| 18315677 | PRE-CLINICAL MODIFIED RNA APPROACHES USED IN LARGE ANIMALS FOR MUSCLE AND VASCULAR REGENERATION | Final Rejection | THE UAB RESEARCH FOUNDATION |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy56.7% of resolved applications examined by Sarah Elizabeth Allen were allowed (30 resolved cases), compared with 45.4% across Art Unit 1637 over the last five years.
This examiner's interview lift is +33.3 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Sarah Elizabeth Allen took 1,314 days on average from filing to allowance.
Sarah Elizabeth Allen examines applications in Art Unit 1637 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
